Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Xeljanz
|
| Active substance |
tofacitinib citrate
|
| Therapeutic area (MeSH) |
Arthritis, Rheumatoid
|
| Procedure number |
EMEA/H/C/004214
|
| Regulatory outcome |
Variation
|
| DHPC type |
Safety signal
|
| Human ATC code |
L04AA29
|
| Dissemination date |
06/07/2021
|